Latigo Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:LTGO Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
10 Aug 26	BuyUS$2,520,000	Foresite Capital Management, LLC	Company		140,000	US$18.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LTGO?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	114,453	0.181%
Individual Insiders	1,134,510	1.79%
Institutions	5,643,436	8.92%
General Public	26,778,672	42.3%
VC/PE Firms	29,566,959	46.8%

Dilution of Shares: LTGO only recently listed within the past 12 months

Top Shareholders

Top 10 shareholders own 57.65% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
20.9%	Westlake Village BioPartners	13,199,669	US$245.0m	0%	no data
14.3%	Foresite Capital Management, LLC	9,041,328	US$167.8m	0%	11.36%
11.6%	5AM Venture Management, LLC	7,325,962	US$136.0m	0%	26.83%
4.98%	Blue Owl Credit Private Fund Advisors LLC	3,146,780	US$58.4m	0%	no data
3.95%	Deep Track Capital, LP	2,496,656	US$46.3m	0%	0.66%
0.84%	Neil Singla	532,795	US$9.9m	0%	no data
0.52%	Timothy Walbert	329,819	US$6.1m	0%	no data
0.26%	Timothy Lugo	166,354	US$3.1m	0%	no data
0.18%	Farzan Trust	114,453	US$2.1m	0%	no data
0.17%	Sara Bonstein	105,542	US$2.0m	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/11 03:38
End of Day Share Price	2026/08/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Latigo Biotherapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.